Nasus Pharma Ltd. (NSRX)

Market Cap	31.24M
Revenue (ttm)	n/a
Net Income	-1.91M
EPS	-0.26
Shares Out	11.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,085
Open	2.550
Previous Close	2.480
Day's Range	2.510 - 2.670
52-Week Range	2.400 - 9.990
Beta	n/a
Analysts	Strong Buy
Price Target	20.50 (+671.37%)
Earnings Date	Mar 20, 2026

About NSRX

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and i...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Aug 14, 2025
• Employees: 2
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: NSRX
• Website: https://www.nasuspharma.com

Analyst Summary

According to 2 analysts, the average rating for NSRX stock is "Strong Buy." The 12-month stock price target is $20.5, which is an increase of 671.37% from the latest price.

Price Target

$20.5

(671.37% upside)

Analyst Consensus: Strong Buy